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Summary
Background Pyrazinamide and ﬂ uoroquinolones are essential antituberculosis drugs in new rifampicin-sparing 
regimens. However, little information about the extent of resistance to these drugs at the population level is available.
Methods In a molecular epidemiology analysis, we used population-based surveys from Azerbaijan, Bangladesh, Belarus, 
Pakistan, and South Africa to investigate resistance to pyrazinamide and ﬂ uoroquinolones among patients with 
tuberculosis. Resistance to pyrazinamide was assessed by gene sequencing with the detection of resistance-conferring 
mutations in the pncA gene, and susceptibility testing to ﬂ uoroquinolones was conducted using the MGIT system.
Findings Pyrazinamide resistance was assessed in 4972 patients. Levels of resistance varied substantially in the 
surveyed settings (3·0–42·1%). In all settings, pyrazinamide resistance was signiﬁ cantly associated with rifampicin 
resistance. Among 5015 patients who underwent susceptibility testing to ﬂ uoroquinolones, proportions of resistance 
ranged from 1·0–16·6% for oﬂ oxacin, to 0·5–12·4% for levoﬂ oxacin, and 0·9–14·6% for moxiﬂ oxacin when tested at 
0·5 μg/mL. High levels of oﬂ oxacin resistance were detected in Pakistan. Resistance to moxiﬂ oxacin and gatiﬂ oxacin 
when tested at 2 μg/mL was low in all countries.
Interpretation Although pyrazinamide resistance was signiﬁ cantly associated with rifampicin resistance, this drug 
may still be eﬀ ective in 19–63% of patients with rifampicin-resistant tuberculosis. Even though the high level of 
resistance to oﬂ oxacin found in Pakistan is worrisome because it might be the expression of extensive and unregulated 
use of ﬂ uoroquinolones in some parts of Asia, the negligible levels of resistance to fourth-generation ﬂ uoroquinolones 
documented in all survey sites is an encouraging ﬁ nding. Rational use of this class of antibiotics should therefore be 
ensured to preserve its eﬀ ectiveness.
Funding Bill & Melinda Gates Foundation, United States Agency for International Development, Global Alliance for 
Tuberculosis Drug Development.
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Introduction
With 9·6 million new cases and 1·5 million deaths 
estimated in 2014, tuberculosis represents a major global 
health problem and ranks alongside HIV as a leading 
cause of infectious-disease-related deaths.1 Although 
global incidence has been falling slowly during the past 
decade, the number of people aﬀ ected every year remains 
daunting. Among the most serious obstacles to successful 
prevention and treatment of tuberculosis are the 
inadequate identiﬁ cation of individuals with latent 
tuberculosis infection who are at highest risk of developing 
the disease,2 insuﬃ  cient capacity of health systems to 
rapidly identify and diagnose all tuberculosis cases 
(especially those with drug resistance),3 inappropriate 
management of contacts of infectious cases, long duration 
of treatment (especially for drug-resistant tuberculosis),4 
concurrent infection with HIV, and worldwide spread of 
Mycobacterium tuberculosis strains that are resistant to the 
most eﬀ ective antituberculosis agents.
To accelerate global progress in the control of 
tuberculosis, new drugs and shorter, easily administered 
regimens are needed to treat all forms of tuberculosis, 
including multidrug-resistant and extensively drug-
resistant tuberculosis.
The use of a fourth-generation ﬂ uoroquinolone (ie, 
moxiﬂ oxacin or gatiﬂ oxacin) to shorten the treatment of 
drug-susceptible tuberculosis to 4 months has been 
recently assessed in three separate large trials (OFLOTUB,5 
REMoxTB,6 and RIFAQUIN7). Unfortunately, none of 
these trial ﬁ ndings showed non-inferiority compared with 
the WHO-recommended 6-month standard regimen for 
the treatment of tuberculosis.8
A few new antituberculosis drugs have undergone 
clinical evaluation over the past decade. These include 
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bedaquiline (a diary quinoline) and delamanid (a 
nitroimidazole), which have been recently approved by 
national regulatory authorities and recommended by 
WHO1 for use in selected patients with multidrug-
resistant tuberculosis. Additionally, pretomanid, another 
nitroimidazole, is under evaluation in short multidrug 
regimens for the treatment of drug-susceptible and 
drug-resistant tuberculosis.9
Although individual new drugs are important, there 
remains a programmatic need for eﬀ ective and shorter 
regimens, particularly for drug-resistant tuberculosis.10,11 
Many of the potential new regimens being proposed or 
tested contain at least one or more of the existing 
antituberculosis drugs. Notably, the combination of 
pyrazinamide plus moxiﬂ oxacin or gatiﬂ oxacin is 
considered essential in novel rifampicin-sparing 
regimens for the treatment of tuberculosis9,12 and in 
shorter regimens for the treatment of multidrug-resistant 
tuberculosis.10,11
When resistance to an individual drug within a treatment 
regimen emerges, a reduction in treatment eﬃ  cacy is 
usually the result. Additionally, there is greater potential 
for generating resistance to the remaining drugs in the 
regimen. Ideally, a new regimen would be introduced in a 
population that has little or no pre-existing resistance. 
Therefore, an understanding of the background prevalence 
of resistance to all drugs included in new regimens is 
needed to assess the feasibility of shorter regimens and the 
need for drug-susceptibility testing to accompany regimen 
introduction.13 Whereas levels of rifampicin and isoniazid 
resistance are routinely monitored in most tuberculosis-
endemic countries, susceptibility testing to ﬂ uoro-
quinolones and pyrazinamide is not routinely performed 
as part of drug resistance surveillance.14 Therefore, little 
population-representative surveillance data about levels of 
resistance to these drugs are  available.
In this Article, we present the results of the ﬁ rst 
population-based surveys investigating levels of resistance 
Research in context
Evidence before this study
The combination of pyrazinamide plus a fourth-generation 
ﬂ uoroquinolone (moxiﬂ oxacin or gatiﬂ oxacin) is considered 
essential in novel rifampicin-sparing regimens for the 
treatment of tuberculosis and in shorter regimens for the 
treatment of multidrug-resistant tuberculosis. Understanding 
the background prevalence at population level of resistance to 
these drugs is critical to assess the feasibility of introducing new 
and shorter regimens in tuberculosis control programmes and 
the need for drug-susceptibility testing to accompany the 
introduction of these new regimens. For the past 20 years, 
levels of resistance to the most powerful ﬁ rst-line 
antituberculosis drugs, rifampicin and isoniazid, have been 
monitored in more than 150 countries worldwide through 
routine surveillance or ad-hoc population-based surveys. 
Results of these studies are reported to WHO. Susceptibility 
testing to ﬂ uoroquinolones and pyrazinamide is not routinely 
performed on all tuberculosis cases as part of drug resistance 
surveillance eﬀ orts. Therefore, population-representative 
surveillance data on levels of resistance to pyrazinamide and 
fourth-generation ﬂ uoroquinolones (moxiﬂ oxacin or 
gatiﬂ oxacin) among all patients with tuberculosis do not exist 
at present. We searched MEDLINE (1966 to March 20, 2016) 
and Embase (1980 to March 20, 2016), using the terms 
“tuberculosis”, “drug”, “resistance”, and “surveillance”, with 
restriction to English, French, and Spanish results. We also 
searched the database of the WHO global project on 
antituberculosis drug resistance surveillance, containing results 
of all published and unpublished national population-based 
antituberculosis drug resistance surveys and surveillance 
conducted worldwide (1994 to March 20, 2016).
Added value of this study
This study presents the results of the ﬁ rst population-based 
surveys investigating levels of resistance to pyrazinamide, 
oﬂ oxacin, levoﬂ oxacin, moxiﬂ oxacin, and gatiﬂ oxacin among 
patients with tuberculosis in countries with high burden of 
tuberculosis and multidrug-resistant tuberculosis. In routine 
surveillance and patient management, testing for resistance to 
these drugs is restricted to certain patient groups, such as those 
with rifampicin resistance or a history of previous treatment for 
tuberculosis. This dataset therefore provides essential insight 
into the background proportions of resistance to these drugs at 
population level and in particular among newly diagnosed 
tuberculosis cases. Our work oﬀ ers insight into the feasibility of 
introducing new tuberculosis treatment regimens and strategies 
for drug-susceptibility testing in these settings.
Implications of all the available evidence
Our results have programmatic implications for both treatment 
strategies and investment opportunities in the development 
and implementation of new diagnostic technologies. This work 
shows that the presence of rifampicin resistance, which 
currently is easily identiﬁ ed thanks to the wide availability of 
new rapid molecular technology, should prompt attention to 
the possibility of the simultaneous presence of resistance to 
pyrazinamide and, in some settings, the earlier generation 
ﬂ uoroquinolones. At the same time, resistance to the latest 
generation ﬂ uoroquinolones at the clinical breakpoint is still 
uncommon. This is a crucial ﬁ nding for the design of standard 
regimens in diﬀ erent settings, and for guidance to regimen 
developers and diagnostic manufacturers. Our ﬁ ndings support 
public health policy makers in prioritisation and introduction of 
new regimens and algorithms for drug-susceptibility testing, 
and call for a rethinking of surveillance needs to ensure that 
more and better data are available to understand levels of 
resistance to pyrazinamide and ﬂ uoroquinolones in diﬀ erent 
epidemiological settings and patient groups. 
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to pyrazinamide, oﬂ oxacin, levoﬂ oxacin, moxiﬂ oxacin, 
and gatiﬂ oxacin among patients with tuberculosis in 
countries with a high burden of tuberculosis and multi-
drug-resistant tuberculosis. We also investigate levels of 
cross resistance among ﬂ uoroquinolones. 
Methods
Study design and participants
Drug resistance surveys are specially designed studies to 
measure antituberculosis drug resistance among a 
representative sample of notiﬁ ed patients with 
pulmonary tuberculosis. Details about the design of drug 
resistance surveys are provided elsewhere.14 Data 
presented in this Article were gathered from isolates 
from patients with tuberculosis enrolled in national 
surveys in Azerbaijan (2013),15 Bangladesh (2011),16 
Pakistan (2013),17 and in subnational surveys in Minsk 
city, Belarus (2010)18 and in Gauteng and KwaZulu Natal 
provinces of South Africa (2014).19 These countries were 
selected because they represent a variety of programmatic 
and epidemiological settings. They all have high 
tuberculosis burden, with tuberculosis incidence varying 
between 58 per 100 000 and 834 per 100 000 population 
and proportion of tuberculosis cases with rifampicin 
resistance ranging from 4·9% to 49·1% (appendix). In all 
of these countries, uncomplicated tuberculosis is treated 
in the public health sector using a standardised regimen 
recommended by WHO.8 In Bangladesh and Pakistan in 
particular, a substantial number of patients are treated by 
private practitioners with variable drug combinations 
and schemes.
Procedures
Sputum samples collected from patients enrolled in these 
surveys underwent culture and susceptibility testing to 
ﬁ rst-line antituberculosis drugs at the National 
tuberculosis Reference Laboratory using either the 
LJ proportion method (Azerbaijan, Bangladesh, Pakistan) 
or MGIT 960 (Becton Dickinson, Sparks, MD, USA; 
Belarus and South Africa). Isolates were then sent to 
selected WHO tuberculosis supranational reference 
laboratories where testing for resistance to pyrazinamide, 
oﬂ oxacin, levoﬂ oxacin, moxiﬂ oxacin, and gatiﬂ oxacin was 
performed. Laboratory methods were standardised and 
all laboratories successfully passed proﬁ ciency testing for 
pyrazinamide and ﬂ uoroquinolones before starting the 
project. Resistance to pyrazinamide was assessed by 
sequencing for the detection of resistance-conferring 
mutations in the pncA gene (Rv2043c) and the promoter, 
located in the Rv2044c–Rv2043c intergenic region. The 
technologies employed were those already in use at the 
supranational reference laboratories and included Sanger 
sequencing using 3730xl (Thermo Fisher Scientiﬁ c, MA, 
USA), next generation sequencing using Hiseq 2500 and 
MiSeq platforms (Illumina, San Diego, CA, USA), and 
Ion Torrent PGM (Thermo Fisher Scientiﬁ c), according 
to manufacturers’ instructions. The role of mutations in 
conferring resistance was assigned on the basis of 
available scientiﬁ c literature20,21 and online databases.22–24 
Additionally, phenotypic susceptibility testing to 
pyrazinamide was conducted on MGIT 960 at the 
concentration of 100·0 μg/mL using the MGIT-PZA kit25 
on all isolates with previously unreported mutations. The 
role of these mutations in conferring resistance was 
assigned according to the observed phenotype.
Susceptibility testing to ﬂ uoroquinolones was conducted 
using the MGIT system and stock solutions of drugs 
prepared in house. All isolates were tested for susceptibility 
to oﬂ oxacin at 2·0 μg/mL and moxiﬂ oxacin at 0·5 μg/mL. 
Any isolate found to be resistant to either oﬂ oxacin at 
2·0 μg/mL or moxiﬂ oxacin at 0·5 μg/mL was subsequently 
tested for resistance to levoﬂ oxacin at 1·5 μg/mL, and 
moxiﬂ oxacin and gatiﬂ oxacin at 2·0 μg/mL. Moxiﬂ oxacin 
was tested at two concentrations because 0·5 μg/mL is 
considered the epidemiological cutoﬀ  and 2·0 μg/mL is 
considered the clinical breakpoint,25 deﬁ ned as the 
concentration of an antibiotic that can be achieved in body 
ﬂ uids or target sites during optimal therapy. Isolates 
found to be susceptible to both oﬂ oxacin at 2·0 μg/mL 
and moxiﬂ oxacin at 0·5 μg/mL were considered to be 
susceptible to levoﬂ oxacin at 1·5 μg/mL, and moxiﬂ oxacin 
and gatiﬂ oxacin at 2·0 μg/mL.
Statistical analysis
We analysed data using version 12.0 of the Stata package, 
stratiﬁ ed for new cases, previously treated cases, all 
cases combined, cases of rifampicin-susceptible tuber-
culosis, and cases of rifampicin-resistant tuberculosis to 
investigate the association of resistance with treatment 
history and rifampicin resistance status. Due to the 
failure to regrow and test all strains, multiple imputation 
of missing values was performed across all settings for 
all drugs. Final imputation models for each drug 
included the following variables: age, sex, history of 
previous treatment, and rifampicin resistance status. 
Proportions of resistance within each group and 95% 
CIs were calculated by logistic regression, specifying 
robust standard errors to account for the cluster-based 
survey design in some countries (Bangladesh, Pakistan, 
South Africa). For drugs without any resistant cases, 
95% CIs were calculated using the normal approximation 
to the binomial.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
In this retrospective study, not all isolates collected 
during the original surveys could be successfully 
regrown. The proportions of the original survey strains 
See Online for appendix
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that could not be retrieved due to poor growth 
varied across countries: 5% (41/789) in Azerbaijan, 
29% (389/1344) in Bangladesh, 10% (23/224) in Belarus, 
6% (89/1592) in Pakistan, and 6% (52/929) in Gauteng 
province and 9% (65/756) in KwaZulu Natal province in 
South Africa. Individuals whose sample could not be re-
grown did not diﬀ er from those with viable samples in 
relation to age, sex, history of treatment or rifampicin 
resistance status (data not shown).
Proportions of resistance to pyrazinamide by setting, 
history of previous treatment and rifampicin 
susceptibility are reported in table 1.
A total of 4972 patients were tested to investigate 
resistance to pyrazinamide in the ﬁ ve countries. Levels of 
resistance among all tuberculosis cases varied sub-
stantially (3·0–42·1% in the surveyed settings) and were 
lowest in Bangladesh, Pakistan, and South Africa. In all 
countries and for all patient groups, levels of resistance 
to pyrazinamide did not statistically diﬀ er from the levels 
of resistance to rifampicin (appendix); the only exception 
was Pakistan, where pyrazinamide resistance was 
signiﬁ cantly lower than rifampicin resistance in all 
patient groups (p<0·0001). Proportions of pyrazinamide 
resistance were signiﬁ cantly higher among patients with 
rifampicin-resistant tuberculosis (compared with 
patients with rifampicin-susceptible tuberculosis), and 
among patients previously treated for tuberculosis 
(compared with those never treated for tuberculosis) in 
almost all settings.
5015 patients were tested to investigate resistance to 
ﬂ uoroquinolones. Proportions of resistance to 
individual ﬂ uoroquinolones by setting, history of 
previous treatment, and rifampicin susceptibility are 
described in table 2 (oﬂ oxacin), table 3 (levoﬂ oxacin), 
Azerbaijan Bangladesh Belarus 
(Minsk city)
Pakistan South Africa 
(Gauteng)
South Africa 
(KwaZulu Natal)
New tuberculosis cases 530, 10·2%
(7·6–12·8)
751, 2·6%
(1·4–3·8)
144, 30·0%
(22·6–37·3)
1299, 2·1%
(1·3–2·9)
648, 2·8%
(1·5–4·1)
444, 2·0%
(0·8–3·3)
Previously treated 
tuberculosis cases
218, 17·9%
(12·7–23·0)
203, 13·8%
(8·8–18·8)
57, 69·9%
(58·4–81·4)
201, 8·9%
(5·1–12·8)
145, 4·7%
(1·5–7·8)
128, 10·5%
(5·1–15·8)
All tuberculosis cases 748, 12·6%
(10·1–15·0)
955, 5·1%
(3·4–6·8)
201, 42·1%
(35·4–48·8)
1500, 3·0%
(2·0–4·0)
877, 3·1%
(1·9–4·4)
691, 3·9%
(2·4–5·4)
Rifampicin susceptible 619, 2·2%
(1·1–3·4)
892, 2·5%
(1·3–3·6)
103, 4·2%
(0·1–8·3)
1397, 0·5%
(0·1–0·8)
838, 1·3%
(0·4–2·2)
657, 1·3%
(0·4–2·3)
Rifampicin resistant 129, 59·9%
(51·0–68·9)
63, 36·7%
(25·9–47·4)
98, 81·3%
(73·7–88·9)
103, 39·5%
(30·1–48·9)
39, 39·1%
(22·9–55·3)
34, 49·1%
(32·7–65·5)
Resistance in rifampicin 
resistant vs rifampicin 
susceptible
<0·0001 <0·0001 <0·0001 <0·0001 <0·0001 <0·0001
Resistance in newly vs 
previously treated
0·004 <0·0001 <0·0001 <0·0001 0·169 <0·0001
Data are number tested, % resistant (95% CI) or p value. 
Table 1: Results of sequencing of the pncA gene (associated with pyrazinamide resistance)
Azerbaijan Bangladesh Belarus 
(Minsk city)
Pakistan South Africa 
(Gauteng)
South Africa 
(Kwazulu Natal)
New tuberculosis cases 528, 3·4%
(1·9–5·0)
736, 4·4%
(2·6–6·2)
141, 7·0%
(2·7–11·3)
1301, 11·2%
(7·8–14·7)
716, 1·0%
(0·1–1·8)
437, 1·0%
(0·0–2·1)
Previously treated tuberculosis 
cases
220, 8·6%
(5·0–12·3)
196, 9·2%
(5·1–13·3)
55, 38·8%
(26·2–51·4)
202, 15·1%
(10·0–20·3)
153, 0·8%
(0·0–2·5)
125, 2·0%
(0·0–4·2)
All tuberculosis cases 748, 5·0%
(3·4–6·6)
933, 5·5%
(3·7–7·3)
196, 16·6%
(11·4–21·9)
1503, 11·8%
(8·7–14·9)
960, 1·0%
(0·0–1·8)
675, 1·3%
(0·4–2·2)
Rifampicin susceptible 618, 0·7%
(0·0–1·3)
873, 4·6%
(3·0–6·2)
99, 2·9%
(0·0–6·3)
1401, 11·1%
(7·8–14·3)
919, 0·4%
(0·0–0·9)
637, 0·2%
(0·0–0·7)
Rifampicin resistant 130, 25·0%
(17·6–32·4)
60, 16·0%
(6·3–25·7)
97, 30·7%
(21·5–40·0)
102, 21·8%
(13·1–30·5)
41, 12·3%
(1·5–23·2)
33, 18·3%
(5·7–31·0)
Resistance in rifampicin 
resistant vs rifampicin 
susceptible
<0·0001 0·001 <0·0001 0·009 <0·0001 <0·0001
Resistance in newly vs 
previously treated
0·004 0·014 <0·0001 0·186 0·868 0·383
Data are number tested, % resistant (95% CI) or p value. 
Table 2: Oﬂ oxacin 2·0 μg/mL susceptibility testing results
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table 4 (moxiﬂ oxacin), and table 5 (gatiﬂ oxacin). Within 
a particular country, the proportion of all cases with 
resistance was similar for three drugs (oﬂ oxacin, 
levoﬂ oxacin, and moxiﬂ oxacin 0·5 μg/mL). Comparing 
among countries, the resistance values for all cases 
ranged from 1·0% to 16·6% (oﬂ oxacin), 0·5% to 12·4% 
Azerbaijan Bangladesh Belarus 
(Minsk city)
Pakistan South Africa 
(Gauteng)
South Africa 
(KwaZulu Natal)
New tuberculosis cases 527, 2·2%
(1·2–4·0)
729, 3·3%
(1·7–5·0)
141, 4·7%
(1·2–8·1)
1299, 10·1%
(6·7–13·4)
705, 0·5%
(0·0–1·1)
419, 0·5%
(0·0–1·3)
Previously treated 
tuberculosis cases
220, 6·9%
(3·6–10·3)
192, 5·4%
(2·6–8·3)
55, 30·3%
(18·7–41·9)
201, 14·9%
(9·8–19·9)
151, 0·5%
(0·0–1·2)
121, 0·9%
(0·0–2·6)
All tuberculosis cases 747, 3·9%
(2·5–5·3)
921, 3·8%
(2·3–5·3)
196, 12·4%
(7·8–17·0)
1500, 10·7%
(7·7–13·7)
945, 0·5%
(0·0–1·1)
650, 0·6%
(0·0–1·3)
Rifampicin susceptible 618, 0·5%
(0·0–1·1)
866, 3·6%
(2·1–5·2)
99, 2·8%
(0·0–6·0)
1401, 10·3%
(7·1–13·5)
806, 0·2%
(0·0–0·9)
620, 0·3%
(0·0–1·4)
Rifampicin resistant 129, 19·4%
(12·5–26·3)
56, 5·5%
(0·0–12·0)
97, 22·4%
(14·2–30·6)
99, 21·8%
(13·1–30·5)
39, 7·0%
(0·0–15·1)
30, 7·9%
(0·0–17·5)
Resistance in rifampicin 
resistant vs rifampicin 
susceptible
<0·0001 0·537 0·002 0·151 0·040 0·040
Resistance in newly vs 
previously treated
0·007 0·156 <0·0001 0·100 0·280 0·661
Data are number tested, % resistant (95% CI) or p value.
Table 3: Levoﬂ oxacin 1·5 μg/mL susceptibility testing results
Azerbaijan Bangladesh Belarus 
(Minsk city)
Pakistan South Africa 
(Gauteng)
South Africa 
(KwaZulu Natal)
0·5 μg/mL
New tuberculosis cases 528, 2·2%
(0·9–3·4)
736, 3·8%
(2·2–5·4)
141, 6·3%
(2·2–10·4)
1301, 7·5%
(5·9–9·1)
709, 0·8%
(0·0–1·6)
421, 0·6%
(0·0–1·4)
Previously treated tuberculosis 
cases
220, 7·0%
(3·6–10·4)
196, 7·0%
(3·7–10·4)
55, 33·5%
(21·7–45·4)
202, 12·1%
(7·3–16·8)
152, 0·9%
(0·0–2·8)
123, 2·1%
(0·0–4·3)
All tuberculosis cases 748, 3·6%
(2·3–5·0)
933, 4·5%
(2·9–6·1)
196, 14·6%
(9·6–19·5)
1503, 8·1%
(6·7–9·6)
951, 0·9%
(0·0–1·7)
654, 1·0%
(0·2–1·7)
Rifampicin susceptible 618, 0·5%
(0·0–1·1)
873, 3·9%
(2·4–5·3)
99, 2·7%
(0·0–5·9)
1401, 7·7%
(6·1–9·3)
910, 0·5%
(0·0–1·1)
621, 0·3%
(0·0–0·8)
Rifampicin resistant 130, 17·9%
(11·2–24·5)
60, 12·2%
(3·7–20·7)
97, 26·8%
(18·0–35·7)
102, 13·8%
(6·3–21·4)
41, 8·4%
(0·0–18·4)
33, 12·2%
(2·2–22·2)
Resistance in rifampicin resistant vs 
rifampicin susceptible
<0·0001 0·007 <0·0001 0·075 <0·0001 <0·0001
Resistance in newly vs previously 
treated
0·002 0·044 <0·0001 0·053 0·919 0·174
2·0 μg/mL
New tuberculosis cases 528, 0·4%
(0·0–1·0)
732, 0·4%
(0·0–1·0)
141, 1·2%
(0·0–3·3)
1299, 0·4%
(0·0–0·8)
707, 0·5%
(0·0–1·4)
420, 0·0%
(0·0–11·2)
Previously treated tuberculosis 
cases
220, 0·5%
(0·0–1·5)
192, 1·4%
(0·0–3·1)
55, 14·0%
(4·5–23·5)
202, 1·7%
(0·0–4·0)
151, 0·7%
(0·0–2·0)
121, 0·0%
(0·0–3·0)
All tuberculosis cases 748, 0·5%
(0·0–1·0)
925, 0·7%
(0·0–1·3)
196, 5·1%
(1·7–8·6)
1501, 0·5%
(0·0–1·1)
948, 0·5%
(0·0–1·1)
651, 0·0%
(0·0–0·6)
Rifampicin susceptible 618, 0·9%
(0·0–3·7)
869, 0·4%
(0·0–0·9)
99, 4·5%
(0·0–13·9)
1401, 0·5%
(0·0–1·0)
908, 0·3%
(0·0–0·7)
620, 0·0%
(0·0–0·6)
Rifampicin resistant 130, 2·0%
(0·0–5·6)
56, 3·2%
(0·0–8·3)
97, 9·2%
(3·1–15·3)
100, 1·4%
(0·0–4·3)
40, 3·8%
(0·0–10·8)
31, 0·0%
(0·0–11·2)
Resistance in rifampicin resistant vs 
rifampicin susceptible
0·410 0·051 0·270 0·316 0·008 ··
Resistance in newly vs previously 
treated
0·926 0·247 0·007 0·132 0·653 ··
Data are number tested, % resistant (95% CI) or p value.
Table 4: Moxiﬂ oxacin 0·5 μg/mL and 2·0 μg/mL susceptibility testing results
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(levoﬂ oxacin), and 0·9% to 14·6% (moxiﬂ oxacin 
0·5 μg/mL). By contrast, the ranges for resistance 
among all cases for moxiﬂ oxacin 2 μg/mL and 
gatiﬂ oxacin were 0·0–5·1% and 0·0–2·5%, respectively, 
and thus were both lower and less variable.
The proportion of new cases of ﬂ uoroquinolone 
resistance was signiﬁ cantly lower than the proportion of 
rifampicin resistance cases in all countries except 
Bangladesh and Pakistan. Higher levels of oﬂ oxacin 
resistance were found in all settings among rifampicin-
resistant tuberculosis cases compared with rifampicin-
susceptible tuberculosis cases, but this association was 
not signiﬁ cant in any setting when compared with the 
other ﬂ uoroquinolones. Finally, we observed higher 
resistance in retreatment than in new cases, but this 
ﬁ nding was statistically signiﬁ cant in only half or fewer 
of the six settings.
Of the 303 isolates that were resistant to oﬂ oxacin in 
this study, drug-susceptibility testing results for all other 
ﬂ uoroquinolones were available for 282 (93%). 
Proportions of cross resistance among oﬂ oxacin-resistant 
isolates are presented in table 6 and were high for 
levoﬂ oxacin (87%), and moxiﬂ oxacin when tested at 
0·5 μg/mL (72%). However, cross resistance remained 
very low between oﬂ oxacin and moxiﬂ oxacin (when 
tested at 2·0 μg/mL; 7%), and gatiﬂ oxacin (2%).
Discussion
In this multicountry survey, we present the ﬁ rst 
population-based data for the prevalence of resistance to 
pyrazinamide and ﬂ uoroquinolones among patients with 
tuberculosis in high-burden countries. In routine 
surveillance and patient management, testing for 
resistance to these drugs is restricted to particular patient 
groups, such as those with rifampicin resistance or a 
history of previous tuberculosis treatment. This dataset 
therefore provides essential insight into background 
levels of resistance and the feasibility of introducing new 
tuberculosis treatment regimens and strategies for drug-
susceptibility testing in these settings.
Pyrazinamide is a crucial component of the most 
commonly used short-course regimen for the treatment 
of tuberculosis recommended by WHO worldwide,8 and 
also of second-line regimens for the treatment of 
multidrug-resistant tuberculosis.11 In the countries 
investigated, our study showed no signiﬁ cant diﬀ erence 
in the overall levels of resistance to pyrazinamide and 
rifampicin, with the only exception being Pakistan where 
pyrazinamide resistance was signiﬁ cantly lower than 
rifampicin resistance. Additionally, pyrazinamide 
resistance was signiﬁ cantly associated with rifampicin 
resistance in all settings, conﬁ rming that the vast 
majority of the burden of pyrazinamide resistance is 
among patients with rifampicin resistance who can be 
rapidly identiﬁ ed using existing molecular tests. 
Nonetheless, for a substantial proportion of patients with 
rifampicin-resistant tuberculosis (19–63%, based on the 
ﬁ ndings of this study; table 1), pyrazinamide could still 
be eﬀ ective. These ﬁ ndings have two important 
implications. First, rifampicin-sparing regimens that 
include pyrazinamide might not be more eﬀ ective than 
the current ﬁ rst-line regimen for the treatment of 
tuberculosis at the population level, given that levels of 
No resistant 
strains
No susceptible 
strains
% resistant 
strains
Oﬂ oxacin (2·0 μg/mL) 282 0 100%
Levoﬂ oxacin (1·5 μg/mL) 245 37 87%
Moxiﬂ oxacin (0·5 μg/mL) 203 79 72%
Moxiﬂ oxacin (2·0 μg/mL) 19 263 7%
Gatiﬂ oxacin (2·0 μg/mL) 7 275 2%
Table 6: Cross resistance among ﬂ uoroquinolones 
Azerbaijan Bangladesh Belarus 
(Minsk city)
Pakistan South Africa 
(Gauteng)
South Africa 
(KwaZulu Natal)
New tuberculosis cases 528, 0·6%
(0·0–1·4)
729, 0·0%
(0·0–0·5)
141, 1·2%
(0·0–3·2)
1299, 0·0%
(0·0–0·3)
705, 0·0%
(0·0–0·5)
419, 0·0%
(0·0–0·9)
Previously treated 
tuberculosis cases
220, 0·5%
(0·0–1·5)
192, 0·0%
(0·0–1·9)
55, 5·4%
(0·0–12·4)
201, 0·0%
(0·0–1·8)
151, 0·0%
(0·0–2·4)
121, 0·0%
(0·0–3·0)
All tuberculosis cases 748, 0·6%
(0·0–1·2)
922, 0·0%
(0·0–0·4)
196, 2·5%
(0·0–5·2)
1500, 0·0%
(0·0–0·2)
945, 0·0%
(0·0–0·4)
650, 0·0%
(0·0–0·6)
Rifampicin susceptible 618, 1·9%
(0·0–6·9)
866, 0·0%
(0·0–0·4)
99, 3·0%
(0·0–7·2)
1401, 0·0%
(0·0–0·3)
906, 0·0%
(0·0–0·4)
620, 0·0%
(0·0–0·6)
Rifampicin resistant 130, 3·3%
(0·1–6·5)
56, 0·0%
(0·0–6·4)
97, 4·0%
(0·0–8·5)
99, 0·0%
(0·0–3·7)
39, 0·0%
(0·0–9·0)
30, 0·0%
(0·0–11·6)
Resistance in rifampicin 
resistant vs rifampicin 
susceptible
0·310 ·· 0·270 ·· ·· ··
Resistance in newly vs 
previously treated
0·818 ·· 0·143 ·· ·· ··
Data are number tested, % resistant (95% CI) or p value.
Table 5: Gatiﬂ oxacin 2·0 μg/mL susceptibility testing results
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resistance to rifampicin and pyrazinamide are similar. 
Second, it is crucial to rapidly distinguish between 
patients who could beneﬁ t from a pyrazinamide-
containing regimen and those for whom inclusion of 
pyrazinamide would not be eﬀ ective. This distinction 
requires rapid molecular tests for the diagnosis of 
pyrazinamide resistance, which do not currently exist.26
As with pyrazinamide, levels of resistance to oﬂ oxacin 
were signiﬁ cantly associated with rifampicin resistance in 
all settings. Levels of resistance to oﬂ oxacin, levoﬂ oxacin, 
and moxiﬂ oxacin at 0·5 μg/mL were similar in all settings 
and signiﬁ cantly lower than those of rifampicin resistance 
in Azerbaijan and Belarus (despite the high prevalence of 
multidrug-resistant tuberculosis in both settings). By 
contrast, in Pakistan (and to a lesser extent in Bangladesh) 
resistance to ﬂ uoroquinolones was higher than rifampicin 
resistance, an alarming ﬁ nding. This ﬁ nding probably 
results from the extensive use of ﬂ uoroquinolones in 
many parts of Asia for the treatment of not only 
tuberculosis but also pneumonia and uncomplicated 
respiratory-tract infections generally.27 In eastern Europe 
and South Africa, ﬂ uoroquinolone resistance is mostly 
conﬁ ned to patients with rifampicin resistance, reﬂ ecting 
use of this class of antibiotics for tuberculosis treatment 
only as second-line therapy. In South Africa, although 
ﬂ uoroquinolones are used for the treatment of pneumonia, 
this use is primarily in the private health sector which is 
often not accessible to patients with tuberculosis.
Resistance to the latest generation of ﬂ uoroquinolones 
(moxiﬂ oxacin and gatiﬂ oxacin at 2·0 μg/mL) was 
extremely low in all settings, even among patients with 
rifampicin resistance. This ﬁ nding can be partly explained 
by the still-infrequent use of fourth-generation ﬂ uoro-
quinolones in most countries. However, it could also 
represent an underestimation of the real problem in view 
of the poor understanding of the association between the 
critical concentration of susceptibility testing of some 
ﬂ uoroquinolones in the laboratory and patient clinical 
outcomes. Recent data suggest that the breakpoint of 
2·0 μg/mL in liquid media might in fact be too high.28,29
The ﬁ nding of extensive cross resistance between 
oﬂ oxacin, levoﬂ oxacin, and moxiﬂ oxacin at 0·5 μg/mL 
(table 6) was expected and in line with the results of 
genetic studies.30 Importantly, cross resistance is still very 
limited between oﬂ oxacin at 2·0 μg/mL and either 
moxiﬂ oxacin at 2·0 μg/mL or gatiﬂ oxacin, but this may 
partly be a consequence of the excessively high 
breakpoints as already discussed. This ﬁ nding supports 
the current recommendations of using moxiﬂ oxacin or 
gatiﬂ oxacin in the treatment of multidrug-resistant 
tuberculosis.11
Our study has two main limitations. The ﬁ rst is related 
to its retrospective nature. Surveys were designed to 
investigate proportions of multidrug-resistant tuber-
culosis, not proportions of resistance to pyrazinamide or 
ﬂ uoroquinolones. As a consequence, when very low levels 
of resistance were detected (particularly to moxiﬂ oxacin at 
2·0 μg/mL and gatiﬂ oxacin), the estimates have wide 
conﬁ dence intervals (tables 4, 5). Although higher levels of 
resistance to most drugs were evident among rifampicin-
resistant and previously treated cases, statistically 
signiﬁ cant diﬀ erences could not be detected in all settings 
due to insuﬃ  cient power. Additionally, a proportion—
generally below 10%, but 29% in Bangladesh—of the 
original surveys strains could not be regrown. Imputation 
of missing values was performed to address this.14
A second limitation is related to the laboratory 
component. Although critical concentrations recom-
mended by WHO25 were used for phenotypic testing, 
recent evidence suggests that some of these thresholds 
might not be ideal.20,28–31 In particular, the low detected 
levels of resistance to moxiﬂ oxacin and gatiﬂ oxacin could 
be a consequence of excessively high breakpoints. To 
estimate levels of resistance to pyrazinamide, we largely 
relied on pncA mutations to avoid problems related to the 
suboptimal reproducibility of phenotypic testing and 
uncertainties around the most appropriate critical 
concentration.20,25,31 It is expected that pncA mutations 
identify around 85–90% of all existing resistance to 
pyrazinamide32,33 and consequently our results may 
slightly underestimate the true burden of resistance. 
Additionally, although only methods recognised by WHO 
were used and all laboratories passed proﬁ ciency testing 
before starting the project, a level of variability in the 
results between laboratories can be expected.
Our ﬁ ndings show that the presence of rifampicin 
resistance, which can be easily identiﬁ ed due to the wide 
availability of new rapid molecular technologies, should 
draw attention to the possibility of the simultaneous 
presence of resistance to pyrazinamide and, in some 
settings, the earlier-generation ﬂ uoroquinolones. At the 
same time, resistance to the latest generation of 
ﬂ uoroquinolones at the clinical breakpoint is still 
uncommon. These ﬁ ndings are crucial for the design of 
standard regimens in diﬀ erent settings, guidance to 
regimen developers and diagnostic manufacturers, and 
the introduction of existing regimens for the treatment 
of drug-resistant tuberculosis (eg, such as shorter 
regimens).11 Choices about prioritisation and 
introduction of new regimens and algorithms for drug-
susceptibility testing must take these data into 
consideration, and surveillance approaches need to be 
re-thought so that better data are available to understand 
levels of resistance to pyrazinamide and ﬂ uoroquinolones 
in diﬀ erent epidemiological settings and patient groups. 
Without this information, the risk of introducing 
ineﬀ ective regimens that are not curative and might 
amplify development of drug resistance, including to 
new agents, remains high. Progress towards drug-
susceptibility testing in all cases and rapid development 
of sequencing technologies for detection of mutations 
expressing resistance to as many drugs as possible is 
crucial to optimise treatment and prevent the creation of 
additional drug resistance.
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